Exegenesis Bio
PrivateLast Round
Series B
Extension
Jun 23, 2021
Total Funding Raised
$70M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Exegenesis Bio operates in Healthcare & Life Sciences and is based in Horsham, Pennsylvania. Its latest recorded funding round was a Series B Extension round in June 2021.
Exegenesis Bio is a biotechnology company that develops cell and gene therapies to treat multiple diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exegenesis Bio Comparables
Compare Exegenesis Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Capsida Biotherapeutics | 86% | |
| Shanghai Refreshgene Technology Co., Ltd. | 84% | |
| Frontera Therapeutics | 83% |
For institutional investors. Book with your work email.
Exegenesis Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 23, 2021 | ||||
| Series B Extension | Feb 1, 2021 | ||||
| Series B | Aug 3, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Exegenesis Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B Extension, Series B |
| Temasek | Series B Extension |
| Lake Bleu Capital | Series B Extension |
| Kaitai Capital | Series B Extension, Series B |
| LYFE Capital | Series B Extension |
| Hillhouse Capital Group | Series B Extension |
| Legend Capital | Series B Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 138% MoM, reaching 4.9K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 11, 2026
Exegenesis Bio develops MDL-201 with Modalis Therapeutics Corporation under a research collaboration and license agreement that combines Exegenesis Bio's muscle-tropic, liver-detargeting EMC181 AAV capsid with Modalis' CRISPR-GNDM(R) technology to advance a mutation-agnostic Duchenne muscular dystrophy therapy designed to selectively activate utrophin.
- partners_withSep 11, 2026
Exegenesis Bio and Modalis Therapeutics Corporation partner under a research collaboration and license agreement that becomes effective Sep 14th '26 to advance MDL-201 for Duchenne muscular dystrophy, with Modalis Therapeutics Corporation receiving rights to use EMC181, an engineered muscle-tropic AAV capsid developed by Exegenesis Bio.
For institutional investors. Book with your work email.
Exegenesis Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Exegenesis Bio's valuation, stock price, and market status.
Is Exegenesis Bio a public or private company?
Exegenesis Bio is a private company.
What is the current stock price of Exegenesis Bio?
Exegenesis Bio is a private company, so its shares have no public market price. Caplight tracks Exegenesis Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Exegenesis Bio worth (valuation)?
Valuation information for Exegenesis Bio is not publicly available.
Can I buy Exegenesis Bio stock?
Exegenesis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Exegenesis Bio's last funding round?
Exegenesis Bio's most recent funding round was Series B Extension on June 23, 2021.
Who are the main investors in Exegenesis Bio?
Key investors in Exegenesis Bio include LYFE Capital, Hillhouse Capital Group, Legend Capital.
Will Exegenesis Bio IPO soon?
No public IPO plans have been announced for Exegenesis Bio.
How can I track Exegenesis Bio secondary market activity?
Caplight tracks bids, offers, and trades in Exegenesis Bio's shares on secondary markets.